Teva and Mircochips Biotech to partner

Teva Pharmaceutical Industries Ltd. and Microchips Biotech Inc. today announced a partnership to discover innovative ways to apply Microchips Biotech’s implantable drug delivery device to Teva’s portfolio of products.

The goal of the partnership is to enhance clinical outcomes for patients on chronic drug therapies.

“The microchip-based implant is truly at the intersection of digital technology and medicine and the future of drug delivery for patients who cannot tolerate needles, require regular self-administered injections, or where compliance is critical to outcomes,” Teva’s President of Global R&D and Chief Scientific Officer Michael Hayden said. “At Teva, we are leading innovation in medicine with promising new drugs and solutions for drug adherence to improve patient outcomes and reduce unnecessary health care complications.”

Microchips Biotech’s electronic device is made up of microchip collections that can store hundreds of therapeutic doses of drug for months or years. It releases each dose at precise times.

“We are thrilled to be aligned with an organization that sees the potential of our technology to transform the way medications are delivered to patients, providing the potential to increase compliance and significantly improve outcomes,” Microchips Biotech CEO Cheryl Blanchard said. “This is the first of what we hope to be many partnerships with industry to leverage our technology across a broad array of therapeutic applications and disease states.”